Detection and clinical significance of tissue factor and microparticle-associated tissue factor in acute myeloid leukemia
-
摘要: 目的:通过检测急性髓系白血病(AML)患者血浆中组因子(TF)及组织因子微粒(MP-TF)的表达,探讨其在AML凝血异常中的临床意义。方法:选择AML住院患者64例(AML组),其中急性早幼粒细胞白血病(APL)22例,非APL 42例;并发弥散性血管内凝血(DIC)22例,未并发DIC 42例。非APL中13例治疗后骨髓完全缓解(CR),APL中15例治疗后骨髓达CR,包含12例APL并发DIC患者。对照组34例均为健康献血员。采用流式细胞术检测MP-TF,ELISA法检测血浆中TF。结果:治疗前AML组MP-TF及TF水平明显高于对照组[(60.90±14.90)%:(45.80±12.03)%,P<0.01;(129.11±37.32)pg/ml:(95.96±19.56)pg/ml,P<0.05]。AML组内,15例治疗后骨髓达CR的APL患者治疗前后MP-TF水平差异有统计学意义[(60.13±8.95)%:(51.65±8.11)%,P<0.05],其中12例APL并发DIC患者治疗前MP-TF及TF水平均高于治疗后[(60.00±9.45)%:(56.70±17.10)%;(155.67±31.14)pg/ml:(122.03±18.41)pg/ml,均P<0.05];13例治疗后骨髓达CR的非APL患者治疗前TF明显高于治疗后[(147.61±27.43)pg/ml:(118.73±20.23)pg/ml,P<0.01]。AML组内,凝血酶原时间(PT)延长>3 s的患者(10例)MP-TF水平明显高于PT延长<3 s及PT正常的患者(54例)[(64.10±9.38)%:(59.40±19.73)%,P<0.05];纤维蛋白降解产物(FDP)异常的患者(24例)TF水平明显高于FDP正常患者(40例)[(152.26±37.89)pg/ml:(112.81±35.47)pg/ml,P<0.05]。结论:MP-TF及TF是参与凝血异常的重要指标,MP-TF较血浆TF能更好地反映TF活性水平,且MP-TF与AML尤其是APL及其凝血异常有密切关系,可作为监测APL疾病病情缓解的有效指标之一。
-
关键词:
- 急性髓系白血病 /
- 组织因子微粒 /
- 急性早幼粒细胞白血病 /
- 弥散性血管内凝血
Abstract: Objective: To detect and explore the clinical significance of tissue factor (TF) and microparticle-associated tissue factor (MP-TF) in acute myeloid leukemia (AML) patients.Method: The peripheral blood in 64 cases of AML with newly diagnosed was collected,including 22 cases of APL,42 cases of non-APL,and 22 cases of AML with DIC and 42 cases of AML without DIC.Thirteen cases of non-APL with bone marrow complete remission (CR),15 cases of APL with bone marrow CR including 12 cases of APL with DIC.Thirty-four cases of normal controls were healthy blood donors.MP-TF was detected by FCM and TF was detected by ELISA.Result: MP-TF and TF in AML patients were both higher than those in the normal controls (P<0.01,P<0.05).MP-TF in the 15 cases of APL with bone marrow CR was higher before chemotherapy than that after chemotherapy (P<0.05).The levels of MP-TF and TF in 12 cases of APL with DIC were higher before chemotherapy than those after chemotherapy (P<0.05).TF in the 13 cases of non-APL with bone marrow CR was higher before chemotherapy than that after chemotherapy (P<0.01).The MP-TF in the patients with PT>3 s was higher than that with normal PT value (P<0.05).TF in the patients with abnormal FDP value was increased than that with normal FDP (P<0.05).Conclusion: MP-TF and TF are important indicators involved in coagulopathy,and MP-TF could better reflect the activity of TF.MP-TF is associated with haemostatic dysfunction in the AML,and it could be used as a factor to monitor disease remission. -
-
[1] 张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:106-213.
[2] LEROYER A S,TEDGUI A,BOULANGER C M.Role of microparticles in atherothrombosis[J].J Intern Med,2008,263:528-537.
[3] ZWICKER J I,TRENOR C C,FURIE B C,et al.Tissue factor bearing-microparticles and thrombus formation[J].Arterioscler Thromb Vasc Biol,2011,31:728-733.
[4] FURIE B.Pathogenesis of thrombosis[J].Hematology Am Soc Hematol Educ Program,2009:255-258.
[5] 方怡,蔡佳翌,钟济华,等.异常剪接组织因子在急性髓系白血病细胞株中的表达研究[J].中国实验血液学杂志,2011,19(2):288-292.
[6] PICCIN A,MURPHY W G,SMITH O P.Circulating microparticles:pathophysiology and clinical implications[J].Blood Rev,2007,21:157-171.
[7] HRON G,KOLLARS M,WEBER H,et al.Tissue factor-positive microparticles:cellular origin and association with coagulation activation in patients with colorectal cancer[J].Thromb Haemost,2007,97:119-123.
[8] KHORANA A A,FRANCIS C W,MENZIES K E,et al.Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer[J].J Thromb Haemost,2008,6:1983-1985.
[9] ZWICKER J I,LIEBMAN H A,NEUBERG D,et al.Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy[J].Clin Cancer Res,2009,15:6830-6840.
[10] AUWERDA J J,YUANA Y,OSANTO S,et al.Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma[J].Thromb and Haemost,2011,105:14-20.
[11] 唐云龙,周燕,王纯斌,等.组织因子相关血小板微粒对恶性淋巴瘤患者血栓发生的提示作用[J].中国实验血液学杂志,2012,20(2):325-328.
[12] ALKINDI S,DENNISON D,PATHARE A.Arterial and venous thrombotic complications with thalidomide in multiple myeloma[J].Arch Med Res,2008,39:257-258.
[13] 汪蕾,胡钧培,叶为德.沙利度胺对血液肿瘤患者致栓作用的初步探究[J].血栓与止血学,2010,16(3):124-126.
[14] ZHOU J,SHI J,HOU J,et al.Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia[J].J Thromb Haemost,2010,8:773-782.
-
计量
- 文章访问数: 47
- PDF下载数: 393
- 施引文献: 0